Menopause Hormone Therapy: Evidence-Based Care with Dr. Rachel Rubin

Shifting Paradigms in Menopause Care

• 🚀 The field of menopause care is undergoing a significant movement, with increased patient and clinician voices driving a shift away from outdated fears.
• 💡 Social media has amplified discussions, allowing patients to access diverse information and participate in shared decision-making regarding their health.
• 🧠 The 2022 Menopause Society guidelines emphasize shared decision-making, moving beyond the restrictive "lowest dose, shortest time possible" approach.

Addressing WHI Misinterpretations and Hormone Nuances

• ⚠️ The Women's Health Initiative (WHI) study, while influential, used older synthetic hormone therapies and older participants, leading to misinterpretations of risks for current hormone therapy (HT).
• 🔬 Current data, including re-analysis of WHI data, suggests no increased risk of stroke or heart attack for women under 70 on systemic HT, and even a decreased risk of breast cancer with unopposed estrogen.
• 🧩 Hormones are not monolithic; distinctions between oral vs. transdermal estrogen, and different progestins, are crucial for safe and effective prescribing.
• 🩺 Transdermal estrogen bypasses the liver's first-pass effect, reducing clotting risk, while micronized progesterone shows no increased breast cancer risk.

Practical Application and Patient Case Discussion

• 🎯 The case of a 60-year-old woman 10 years post-menopause with night sweats, joint pain, and low libido highlights the need for individualized care beyond old fears.
• 📈 Concerns about cardiovascular risk in this patient are addressed by emphasizing that current data, especially with transdermal routes, is reassuring, and HT may even offer benefits like reduced fracture and diabetes risk.
• 💬 Shared decision-making is key, involving a thorough discussion of knowns, unknowns, and patient goals, rather than defaulting to avoidance.

Comprehensive Menopause Treatment Toolbox

• 💡 Vaginal estrogen therapy is highlighted as a safe, effective, and often overlooked treatment for genitourinary syndrome of menopause (GSM), preventing UTIs and improving sexual health.
• 💊 Systemic hormone therapy, including estrogen (patches, gels, rings, oral) and progesterone (micronized progesterone is preferred), is discussed for managing vasomotor symptoms, bone health, and mood.
• ⚡ Testosterone is presented as a valuable option for low libido, with a focus on its safety and efficacy when used appropriately, despite regulatory hurdles.
• 🌟 The vulvar vestibule is identified as a critical, often untreated area contributing to pain with sex and recurrent UTIs, responsive to compounded estrogen-testosterone creams or vaginal DHEA.

Navigating Perimenopause and Long-Term Therapy

• 🔄 For perimenopausal patients, options include birth control pills to suppress ovarian function, or a "quarter to half a tank" approach using low-dose systemic hormones and testosterone to manage fluctuating symptoms.
• ⏳ Hormone therapy is increasingly viewed as potentially lifelong, especially for symptom management and bone health, with data supporting continued use in older adults, particularly with transdermal options.
• 📚 Resources like the International Society for the Study of Women's Sexual Health (ISSWSH) and The Menopause Society provide valuable guidelines and educational materials for clinicians.